Influence of Solid Lipid Nanoparticles on Pharmaco-dynamic Activity of Poorly Oral Bioavailable Drugs
DOI:
https://doi.org/10.37285/ijpsn.2019.13.4.2Abstract
In the recent scenario, lipid nanoparticles gain much attention on the oral absorption of drugs to enhance therapeutic effectiveness after oral administration. Pharmacodynamic activity of drug mainly describes the pharmacological and therapeutic activity of drug to the biological system. Lipid nanoparticles especially solid lipid nanoparticles are made of physiological inert lipid molecules and promotes the lymphatic transport. Abundant literature is available on the effect of lipid nanoparticles and other colloidal carrier systems on the pharmacokinetic parameters of poorly bioavailable drugs, to improve their oral absorption and also respective mechanisms for the improved oral bioavailability. However, little literature is reported on the pharmacodynamic activity and the effect of dose on the pharmacodynamic activity. It is of paramount importance to assess the influence of lipid nanoparticles on pharmacotherapeutic actions of specific drug classes. Therefore, current review is mainly focused on the role of solid lipid nanoparticles on the pharmacodynamic action and advantages of the developed delivery systems with respect to pharmacodynamic activity.
Downloads
Metrics
Keywords:
Oral absorption, Lipid nanoparticles, Lymphatic transport, Pharmacodynamics.
Downloads
Published
How to Cite
Issue
Section
References
Almeida AJ and Eliana S. (2007). Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59(6): 478-490.
Andrew J. Humberstone and William N. Charman. (1997). Lipid-based vehicles for the oral delivery of poorly water-soluble drugs. Adv Drug Deliv Rev 25: 103-128.
Arun B, Narendar D, and Kishan V. (2018). Development of olmesartan medoxomil lipid based nanoparticles and nano-suspension: Preparation, characterization and comparative pharmacokinetic evaluation. Artificial cells, nanomed biotech 46(1):126-137.
Bruce JA (1993). Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 82(10): 979-987.
Chiara D, Federica F, Benedetta F, and Arianna CR (2017). Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: TEMP Effects in an in vivo model. World J gastro entrology 23(23): 4200-4210.
Gondrella U, Dudhipala N, and Veerabrahma K. (2015). Preparation, characterization and in vivo evaluation of felodipine solid lipid nanoparticles to improve the oral bioavailability. Int J Pharma Sci Nanotech 8(4): 2995-3002.
Göppert TM and Müller RH (2005). Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J Drug Target 13(3): 179-187.
Ji H, Tang J, Li M, Ren J, Zheng N, and Wu L (2016). Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin. Drug Deliv 23: 459-470.
Luo Y, Teng Z, Li Y, and Wang Q (2015). Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydra poly 122: 221-229.
Medhi B, Misra S, Sinha VR, and Modi M (2015). Galantamine-loaded solid lipid nanoparticles: Preparation, characterization, and pharmacodynamics evaluations. Alzheimer's and Demen 11(7): 840-890.
Mehnert W and Mäder K (2001). Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 47:165-196.
Mehnert W and Mäder K (2012). Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev. 64: 83-101.
Müller RH, Maaûen, S and Weyhers H (1996). Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN). Int J Pharm 138: 85- 94.
Müller RH, Mäder K, and Gohla S (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm 50: 161-177.
Müller RH, Mehnert W, Lucks JS, Schwarz C, Zur Mühlen A, Weyhers H, Freitas C, and Ruhl D. (1995) Solid lipid nanoparticles (SLN)-An alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 41: 62–69.
Müller RH, Schwarz C, and Zur Muhlen A. (1994). Incorporation of lipophilic drugs and drug release profiles of solid lipid nanoparticles (SLN). Proc Int Symp Control Rel Bioact Mate 21: 146-7.
Nagaraj K, Narendar D, and Kishan V. (2017). Development of olmesartan medoxomil optimized nanosuspension using Box-Behnken design to improve oral bioavailability. Drug Dev Ind Phar 43(7):1186-1196.
Narendar D and Karthik J (2017). Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: Optimization, in vitro and in vivo evaluation. Drug Dev Ind Pharm 43(7): 1205-1214.
Narendar D, Chinna Reddy P, Sunil R, and Rao YM (2012). Development of floating matrix tablets of Ofloxacin and Ornidazole in combined dosage form: in vitro and in vivo evaluation in healthy human volunteers. Int J Drug Deli 4: 462-469.
Narendar D and Govardhan K (2018). Capecitabine lipid nano-particles for anti-colon cancer activity in 1, 2-dimethylhydrazine induced colon cancer: Preparation, cytotoxic, pharmacokinetic and pathological evaluation. Drug Dev Ind Pharm Eraly online, March 44(10): 1572-1582.
Narendar D, Karthik Yadav J, and Thirupathi G (2018). Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artificial cells, nanomed biotech 46(S2): 616-625.
Narendar D and Kishan V (2014). Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharma-cokinetic and pharmacodynamic evaluation. Drug Deliv Early 23(2): 395-404.
Narendar D and Kishan V (2015). Pharmacokinetic and pharma-codynamic studies of nisoldipine loaded solid lipid nanoparticles by central composite design. Drug Dev Ind Pharm 41(12): 1968-1977.
Narendar D and Kishan V. (2017a). Candesartan cilexetil nanoparticles for improved oral bioavailability. Ther deli 8(2): 79-88.
Narendar D and Kishan V (2017b). Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: pharmacokinetic and pharmacodynamic evaluation. Euro J Pharm Biopharm 110(1): 47-57.
Narendar D, Palem CR, Reddy S, and Rao YM (2011). Pharmaceutical development and clinical pharmacokinetic evaluation of gastro retentive floating matrix tablets of levofloxacin. Int J Pharm Sci Nanotech 4(3): 1461-1467.
Narendar D, Someshwar K, Arjun N and Rao YM. (2016). Quality by design approach for development and optimization of Quetiapine Fumarate effervescent floating matrix tablets for improved oral delivery. J Pharm Investig 46(3): 253-263.
Narendar D (2019). A comprehensive review on solid lipid nanoparticles as delivery vehicle for enhanced pharmacokinetic and pharmacodynamic activity of poorly soluble drugs. Int J Pharm Sci Nanotech 12(2): 4421-4440.
Padhye SG and Mangal SN. (2013). Simvastatin Solid lipid nanoparticles for oral delivery: formulation development and in vivo evaluation. Ind J Pharm Sci 75(5): 591-598.
Palem CR, Ramesh G, Narender D, Vamshi Vishnu I, and Rao YM. (2011). Transmucosal delivery of domperidone from bilayered buccal patches: in vitro, ex vivo and in vivo characterization. Arch Pharm Res 34(10):1701-1710.
Pandita D, Kumar S, Poonia N, and Lather V (2014). Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol. Food Res Int 62:1165-1174.
Radtke M and Müller RH (2001a). Novel concept of topical cyclosporine delivery supersaturated SLN™ creams. Int Symp Control Rel Bioact Mater 28: 5161.
Radtke M and Müller RH. (2001b). Stability study of creams containing cyclosporine SLN™. Int Symp Control Rel Bioact Mater 28: 5162.
Sandeep V, Arjun N, and Kishan V (2016). Lacidipine loaded solid lipid nanoparticles for oral delivery: Preparation, characterization and in vivo evaluation. Int J Pharma Sci Nanotech 9(6): 3524-30.
Suvarna G, Narender D, and Kishan V (2015). Preparation, Characterization and in vivo Evaluation of Rosuvastatin Calcium Loaded Solid Lipid Nanoparticles. Int J Pharm Sci Nanotech 8(1): 2779-2785.
Swetha E and Narendar D (2017). Influence of β-Cyclodextrin and Hydroxypropyl-β-Cyclodextrin on Enhancement of Solubility and Dissolution of Isradipine. Int J Pharm Sci Nanotech 10(3): 3752-3757.
Tatke A, Dudhipala N, and Janga KY (2019). In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: tear kinetics and ocular disposition studies. Nanomaterials (Basel) 27: 9(1).
Thirupathi G, Swetha E, and Narendar D (2017). Role of isradipine loaded solid lipid nanoparticles in the pharmacodynamic effect of isradipine in rats. Drug res 67(03): 163-169.
Tirumalesh C, Dinesh S, Narendar D, and Nagaraj B. (2020). Enhanced pharmacokinetic activity of Zotepine via nanostructured lipid carrier system in Wistar rats for oral application. Pharm nanotech 10.2174/ 221173850866620022511 3359.
Zariwala MG, Elsaid N, and Jackson TL (2013). A novel approach to oral iron delivery using ferrous sulphate loaded solid lipid nanoparticles. Int J Pharm 456(2): 400-407.
